The availability of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) such as
liraglutide and semaglutide, and a GLP-1 and glucose dependent insulinotropic polypeptide …

The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2
diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA …

BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective in
diabetes and obesity, reducing hyperglycemia by increasing insulin release and delaying …

Background: Glucagon-like peptide receptor agonists (GLP-1 RAs) are associated with
delayed gastric emptying and may increase the risk of aspiration due to retained gastric …

Background and aims Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to
cause delayed gastric emptying, however the effect on clinical outcomes during upper …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual GLP-1-and
glucose-dependent insulinotropic polypeptide receptor co-agonist tirzepatide (referred to …

Glucagon-like peptide receptor agonists (GLP-1RA) are used to treat type 2 diabetes
mellitus and, more recently, have garnered attention for their effectiveness in promoting …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become one of the most
popular medications for patients with diabetes and obesity. Due to their effects on gut motility …

Abstract BACKGROUND AND AIMS Glucagon-like peptide-1 receptor agonists are
commonly prescribed for diabetes and obesity; however, their use may complicate …

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most
common chronic liver disease worldwide, paralleling the rising pandemic of obesity and type …